Kambara S, Yoshimura M, Okabayashi H, Takahashi H, Ijichi H
Jpn Circ J. 1986 Nov;50(11):1120-7. doi: 10.1253/jcj.50.1120.
The aim of the study was to investigate whether or not the development of hypertension is influenced by chronic treatment with bromocriptine and/or domperidone. Rats treated with DOCA-salt were divided into 4 groups: control with vehicle, bromocriptine, bromocriptine with domperidone, and domperidone. Increased blood pressure by DOCA-salt treatment was significantly suppressed by treatment with bromocriptine and this bromocriptine suppression was significantly blocked by treatment with domperidone. Increased urinary excretion of norepinephrine by DOCA-salt treatment was significantly suppressed by bromocriptine and the inhibiting effect of bromocriptine disappeared with domperidone. In the four groups of rats, there were significant correlations between systolic blood pressure and urinary excretion of norepinephrine, systolic blood pressure and urinary excretion of epinephrine, and urinary excretion of dopamine and sodium. These results suggest that the chronic effect of bromocriptine is to suppress development of DOCA-salt hypertension, mainly through peripheral mechanisms which are involved in the decreased release of norepinephrine.
该研究的目的是调查长期使用溴隐亭和/或多潘立酮治疗是否会影响高血压的发展。用去氧皮质酮-盐(DOCA-盐)处理的大鼠被分为4组:用赋形剂对照、溴隐亭、溴隐亭与多潘立酮联合使用以及多潘立酮组。DOCA-盐处理导致的血压升高被溴隐亭治疗显著抑制,而这种溴隐亭的抑制作用被多潘立酮治疗显著阻断。DOCA-盐处理导致的去甲肾上腺素尿排泄增加被溴隐亭显著抑制,且溴隐亭的抑制作用在使用多潘立酮后消失。在这四组大鼠中,收缩压与去甲肾上腺素尿排泄、收缩压与肾上腺素尿排泄以及多巴胺尿排泄与钠之间存在显著相关性。这些结果表明,溴隐亭的长期作用是主要通过涉及去甲肾上腺素释放减少的外周机制来抑制DOCA-盐性高血压的发展。